AAP
CRBP icon

Arax Advisory Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Arax Advisory Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28 Hold
3
– – ﹤0.01% 5173
2026
Q1 		$28 Hold
3
– – ﹤0.01% 3695
2025
Q4 		$24 Sell
3
-136
-98% -$1.68K ﹤0.01% 4009
2025
Q3 		$1.76K Buy
+139
New +$1.32K ﹤0.01% 3144

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Arax Advisory Partners's CRBP Position: Q2 2026 in Review

Arax Advisory Partners held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 3 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #5173.

Arax Advisory Partners first reported a position in CRBP in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.76K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Arax Advisory Partners held 3 shares of Corbus Pharmaceuticals worth $28 as of Q2 2026.
  • Arax Advisory Partners left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5173 holding.
  • Arax Advisory Partners first reported a position in Corbus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Corbus Pharmaceuticals position peaked at $1.76K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.